aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2022-18-4-426-429ateroskleroz-878Research ArticleМАТЕРИАЛЫ ВТОРОЙ РОССИЙСКОЙ КОНФЕРЕНЦИИ С МЕЖДУНАРОДНЫМ УЧАСТИЕМ «ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ЭНДОКРИНОЛОГИИ: СОВРЕМЕННАЯ СТРАТЕГИЯ РАЗВИТИЯ И ТЕХНОЛОГИИ ПЕРСОНАЛИЗИРОВАННОЙ МЕДИЦИНЫ», г. Новосибирск, 24–25 ноября 2022 г.MATERIALS OF THE 2ND CONFERENCE WITH INTERNATIONAL PARTICIPATION “BASIC RESEARCH IN ENDOCRINOLOGY: A MODERN STRATEGY FOR THE DEVELOPMENT AND TECHNOLOGIES OF PERSONALIZED MEDICINE”, Novosibirsk, November 24–25, 2022Анализ распространенности и заболеваемости надпочечниковой недостаточностью в миреЮкинаМ. Ю.
г. Москва
НуралиеваН. Ф.
г. Москва
ТрошинаЕ. А.
г. Москва
ФГБУ «НМИЦ эндокринологии» Минздрава РоссииRussian Federation202220012023184426429Copyright © Юкина М.Ю., Нуралиева Н.Ф., Трошина Е.А., 20232023Юкина М.Ю., Нуралиева Н.Ф., Трошина Е.А.Юкина М.Ю., Нуралиева Н.Ф., Трошина Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/878
.
ReferencesKong M.F., Jeffcoate W. Eighty-six cases of Addison’s disease. Clin. Endocrinol. (Oxf.), 1994; 41 (6): 757–761. doi: 10.1111/j.1365-2265.1994.tb02790.xKong M.F., Jeffcoate W. Eighty-six cases of Addison’s disease. Clin. Endocrinol. (Oxf.), 1994; 41 (6): 757–761. doi: 10.1111/j.1365-2265.1994.tb02790.xWillis A.C., Vince F.P. The prevalence of Addison’s disease in Coventry, UK. Postgrad. Med. J., 1997; 73 (859): 286–288. doi: 10.1136/pgmj.73.859.286Willis A.C., Vince F.P. The prevalence of Addison’s disease in Coventry, UK. Postgrad. Med. J., 1997; 73 (859): 286–288. doi: 10.1136/pgmj.73.859.286Laureti S., Vecchi L., Santeusanio F., Falorni A. Is the prevalence of Addison’s disease underestimated? J. Clin. Endocrinol. Metab., 1999; 84 (5): 1762. doi: 10.1210/jcem.84.5.5677-7Laureti S., Vecchi L., Santeusanio F., Falorni A. Is the prevalence of Addison’s disease underestimated? J. Clin. Endocrinol. Metab., 1999; 84 (5): 1762. doi: 10.1210/jcem.84.5.5677-7Løvås K., Husebye E.S. High prevalence and increasing incidence of Addison’s disease in western Norway. Clin. Endocrinol. (Oxf.), 2002; 56 (6): 787–791. doi: 10.1046/j.1365-2265.2002.t01-1-01552.xLøvås K., Husebye E.S. High prevalence and increasing incidence of Addison’s disease in western Norway. Clin. Endocrinol. (Oxf.), 2002; 56 (6): 787–791. doi: 10.1046/j.1365-2265.2002.t01-1-01552.xErichsen M.M., Lovas K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B., Carlson J.A., Erlich H., Husebye E.S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab., 2009; 94 (12): 4882–4890. doi: 10.1210/jc.2009-1368Erichsen M.M., Lovas K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B., Carlson J.A., Erlich H., Husebye E.S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab., 2009; 94 (12): 4882–4890. doi: 10.1210/jc.2009-1368Björnsdottir S., Sundström A., Ludvigsson J.F., Blomqvist P., Kampe O., Bensing S. Drug prescription patterns in patients with Addison’s disease: a Swedish population-based cohort study. J. Clin. Endocrinol. Metab., 2013; 98 (5): 2009–2018. doi: 10.1210/jc.2012-3561Björnsdottir S., Sundström A., Ludvigsson J.F., Blomqvist P., Kampe O., Bensing S. Drug prescription patterns in patients with Addison’s disease: a Swedish population-based cohort study. J. Clin. Endocrinol. Metab., 2013; 98 (5): 2009–2018. doi: 10.1210/jc.2012-3561Meyer G., Neumann K., Badenhoop K., Linder R. Increasing prevalence of Addison’s disease in German females: health insurance data 2008–2012. Eur. J. Endocrinol., 2014; 170 (3): 367–373. doi: 10.1530/EJE-13-0756Meyer G., Neumann K., Badenhoop K., Linder R. Increasing prevalence of Addison’s disease in German females: health insurance data 2008–2012. Eur. J. Endocrinol., 2014; 170 (3): 367–373. doi: 10.1530/EJE-13-0756Regal M., Paramo C., Sierra S.M., Garcia-Mayor R.V. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin. Endocrinol. (Oxf.), 2001; 55 (6): 735–740. doi: 10.1046/j.1365-2265.2001.01406.xRegal M., Paramo C., Sierra S.M., Garcia-Mayor R.V. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin. Endocrinol. (Oxf.), 2001; 55 (6): 735–740. doi: 10.1046/j.1365-2265.2001.01406.xTomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., Sheppard M.C., Stewart P.M. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 2001; 357 (9254): 425–431. doi: 10.1016/s0140-6736(00)04006-xTomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., Sheppard M.C., Stewart P.M. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 2001; 357 (9254): 425–431. doi: 10.1016/s0140-6736(00)04006-xShetty V.B., Bower C., Jones T.W., Lewis B.D., Davis E.A. Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period. J. Paediatr. Child. Health, 2012; 48 (11): 1029–1032. doi: 10.1111/j.1440-1754.2012.02584.xShetty V.B., Bower C., Jones T.W., Lewis B.D., Davis E.A. Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period. J. Paediatr. Child. Health, 2012; 48 (11): 1029–1032. doi: 10.1111/j.1440-1754.2012.02584.xGleeson H.K., Wiley V., Wilcken B., Elliott E., Cowell C., Thonsett M., Byrne G., Ambler G. Twoyear pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J. Paediatr. Child. Health, 2008; 44 (10): 554–559. doi: 10.1111/j.1440-1754.2008.01383.xGleeson H.K., Wiley V., Wilcken B., Elliott E., Cowell C., Thonsett M., Byrne G., Ambler G. Twoyear pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J. Paediatr. Child. Health, 2008; 44 (10): 554–559. doi: 10.1111/j.1440-1754.2008.01383.xNascimento M.L., Cristiano A.N.B., Campos T. de, Ohira M., Cechinel E., Simoni G., van de Sande Lee J., Linhares R.M.M., da Silva P.C.A. Avaliação de dez anos de um programa de triagem neonatal para hiperplasia adrenal congênita. Arquivos Brasileiros de Endocrinologia e Metabologia, 2014; 58 (7): 765–771. doi: 10.1590/0004-2730000003310Nascimento M.L., Cristiano A.N.B., Campos T. de, Ohira M., Cechinel E., Simoni G., van de Sande Lee J., Linhares R.M.M., da Silva P.C.A. Avaliação de dez anos de um programa de triagem neonatal para hiperplasia adrenal congênita. Arquivos Brasileiros de Endocrinologia e Metabologia, 2014; 58 (7): 765–771. doi: 10.1590/0004-2730000003310Pezzuti I.L., Barra C.B., Mantovani R.M., Januario J.N., Silva I.N. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J. Pediatr. (Rio J.), 2014; 90 (3): 300–307. doi: 10.1016/j.jped.2013.09.007Pezzuti I.L., Barra C.B., Mantovani R.M., Januario J.N., Silva I.N. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J. Pediatr. (Rio J.), 2014; 90 (3): 300–307. doi: 10.1016/j.jped.2013.09.007Kopacek C., de Castro S.M., Prado M.J., da Silva C.M., Beltrao L.A., Spritzer P.M. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants. 428 BMC Pediatr., 2017; 17 (1): 22. doi: 10.1186/s12887-016-0772-xKopacek C., de Castro S.M., Prado M.J., da Silva C.M., Beltrao L.A., Spritzer P.M. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants. 428 BMC Pediatr., 2017; 17 (1): 22. doi: 10.1186/s12887-016-0772-xZhong K., Wang W., He F., Wang Z. The status of neonatal screening in China, 2013. J. Med. Screen, 2016; 23 (2): 59–61. doi: 10.1177/0969141315597715Zhong K., Wang W., He F., Wang Z. The status of neonatal screening in China, 2013. J. Med. Screen, 2016; 23 (2): 59–61. doi: 10.1177/0969141315597715Schweizer R., Blumenstock G., Mangelsdorf K., Ehehalt S., Rossner L., Dorn T., Binder G., Ranke M.B. Prevalence and incidence of endocrine disorders in children: results of a survey in Baden-Wuerttemberg and Bavaria (EndoPrIn BB) 2000–2001. Klin. Padiatr., 2010; 222 (2): 67–72. doi: 10.1055/s-00291241868Schweizer R., Blumenstock G., Mangelsdorf K., Ehehalt S., Rossner L., Dorn T., Binder G., Ranke M.B. Prevalence and incidence of endocrine disorders in children: results of a survey in Baden-Wuerttemberg and Bavaria (EndoPrIn BB) 2000–2001. Klin. Padiatr., 2010; 222 (2): 67–72. doi: 10.1055/s-00291241868Kim J.H., Choi S., Lee Y.A., Lee J., Kim S.G. Epidemiology and long-term adverse outcomes in korean patients with congenital adrenal hyperplasia: a nationwide study. Endocrinol. Metab. (Seoul), 2022; 37 (1): 138–147. doi: 10.3803/EnM.2021.1328Kim J.H., Choi S., Lee Y.A., Lee J., Kim S.G. Epidemiology and long-term adverse outcomes in korean patients with congenital adrenal hyperplasia: a nationwide study. Endocrinol. Metab. (Seoul), 2022; 37 (1): 138–147. doi: 10.3803/EnM.2021.1328Zetterström R.H., Karlsson L., Falhammar H., Lajic S., Nordenström A. Update on the Swedish Newborn Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Int. J. Neonatal Screening, 2020; 6 (3): 71. doi: 10.3390/ijns6030071Zetterström R.H., Karlsson L., Falhammar H., Lajic S., Nordenström A. Update on the Swedish Newborn Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Int. J. Neonatal Screening, 2020; 6 (3): 71. doi: 10.3390/ijns6030071Silveira E.L., Santos E.P., Bachega T.A.S., Nader I.L., Gross J.L., Elnecave R.H. The actual incidence of congenital adrenal hyperplasia in brazil may not be as high as inferred – an estimate based on a public neonatal screening program in the state of Goiás. J. Pediat. Endocrinol. and Metab., 2008; 21 (5). doi: 10.1515/jpem.2008.21.5.455Silveira E.L., Santos E.P., Bachega T.A.S., Nader I.L., Gross J.L., Elnecave R.H. The actual incidence of congenital adrenal hyperplasia in brazil may not be as high as inferred – an estimate based on a public neonatal screening program in the state of Goiás. J. Pediat. Endocrinol. and Metab., 2008; 21 (5). doi: 10.1515/jpem.2008.21.5.455Dumic K., Krnic N., Skrabic V., Stipancic G., Cvijovic K., Kusec V., Stingl K. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006. Hormone Research in Paediatrics, 2009; 72 (5): 310–314. doi: 10.1159/000245933Dumic K., Krnic N., Skrabic V., Stipancic G., Cvijovic K., Kusec V., Stingl K. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006. Hormone Research in Paediatrics, 2009; 72 (5): 310–314. doi: 10.1159/000245933González E.C., Carvajal F., Frómeta A., Arteaga A.L., Castells E.M., Espinosa T., Coto R., Pérez P.L., Tejeda Y., Del Río L., Segura M.T., Almenares P., Robaina R., Fernández J.L. Newborn screening for congenital adrenal hyperplasia in Cuba: Six years of experience. Clin. Chim. Acta, 2013; 421: 73–78. doi: 10.1016/j.cca.2013.02.020González E.C., Carvajal F., Frómeta A., Arteaga A.L., Castells E.M., Espinosa T., Coto R., Pérez P.L., Tejeda Y., Del Río L., Segura M.T., Almenares P., Robaina R., Fernández J.L. Newborn screening for congenital adrenal hyperplasia in Cuba: Six years of experience. Clin. Chim. Acta, 2013; 421: 73–78. doi: 10.1016/j.cca.2013.02.020Otava F., Novotna D., Kracmar P., Vinohradska H., Stahlova-Hrabincova E., Vrzalova Z., Neumann D., Malikova J., Lebl J., Matern D. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Eur. J. Pediatr., 2012; 171 (6): 935–940. doi: 10.1007/s00431-011-1656-6Otava F., Novotna D., Kracmar P., Vinohradska H., Stahlova-Hrabincova E., Vrzalova Z., Neumann D., Malikova J., Lebl J., Matern D. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Eur. J. Pediatr., 2012; 171 (6): 935–940. doi: 10.1007/s00431-011-1656-6Coulm B. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in Mainland France between 1996 and 2003. Arch. Pediatr. Adolesc. Med., 2012; 166 (2): 113. doi: 10.1001/archpediatrics.2011.774Coulm B. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in Mainland France between 1996 and 2003. Arch. Pediatr. Adolesc. Med., 2012; 166 (2): 113. doi: 10.1001/archpediatrics.2011.774Odenwald B., Dörr H.G., Bonfig W., Schmidt H., Fingerhut R., Wildner M., Nennstiel-Ratzel U. Classic congenital adrenal hyperplasia due to 21-hydroxylase-deficiency: 13 years of neonatal screening and follow-up in Bavaria. Klinische Pädiatrie, 2015; 227 (05): 278–283. doi: 10.1055/s-0035-1554639Odenwald B., Dörr H.G., Bonfig W., Schmidt H., Fingerhut R., Wildner M., Nennstiel-Ratzel U. Classic congenital adrenal hyperplasia due to 21-hydroxylase-deficiency: 13 years of neonatal screening and follow-up in Bavaria. Klinische Pädiatrie, 2015; 227 (05): 278–283. doi: 10.1055/s-0035-1554639Morikawa S., Nakamura A., Fujikura K., Fukushi M., Hotsubo T., Miyata J., Ishizu K., Tajima T. Results from 28 years of newborn screening for congenital adrenal hyperplasia in Sapporo. Clin. Pediatr. Endocrinol., 2014; 23 (2): 35–43. doi: 10.1297/cpe.23.35Morikawa S., Nakamura A., Fujikura K., Fukushi M., Hotsubo T., Miyata J., Ishizu K., Tajima T. Results from 28 years of newborn screening for congenital adrenal hyperplasia in Sapporo. Clin. Pediatr. Endocrinol., 2014; 23 (2): 35–43. doi: 10.1297/cpe.23.35Tsuji A., Konishi K., Hasegawa S., Anazawa A., Onishi T., Ono M., Morio T., Kitagawa T., Kashimada K. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr., 2015; 15: 209–209. doi: 10.1186/s12887-015-0529-yTsuji A., Konishi K., Hasegawa S., Anazawa A., Onishi T., Ono M., Morio T., Kitagawa T., Kashimada K. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr., 2015; 15: 209–209. doi: 10.1186/s12887-015-0529-yHeather N.L., Seneviratne S.N., Webster D., Derraik J.G.B., Jefferies C., Carll J., Jiang Y., Cutfield W.S., Hofman P.L. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994–2013. J. Clin. Endocrinol. Metab., 2015; 100 (3): 1002–1008. doi: 10.1210/jc.2014-3168Heather N.L., Seneviratne S.N., Webster D., Derraik J.G.B., Jefferies C., Carll J., Jiang Y., Cutfield W.S., Hofman P.L. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994–2013. J. Clin. Endocrinol. Metab., 2015; 100 (3): 1002–1008. doi: 10.1210/jc.2014-3168Gidlöf S., Wedell A., Guthenberg C., von Döbeln U., Nordenström A. Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden. JAMA Pediatr., 2014; 168 (6): 567. doi: 10.1001/jamapediatrics.2013.5321Gidlöf S., Wedell A., Guthenberg C., von Döbeln U., Nordenström A. Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden. JAMA Pediatr., 2014; 168 (6): 567. doi: 10.1001/jamapediatrics.2013.5321Khalid J.M., Oerton J.M., Dezateux C., Hindmarsh P.C., Kelnar C.J., Knowles R.L. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Archives of Disease in Childhood, 2012; 97 (2): 101–106. doi: 10.1136/archdischild-2011-300234Khalid J.M., Oerton J.M., Dezateux C., Hindmarsh P.C., Kelnar C.J., Knowles R.L. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Archives of Disease in Childhood, 2012; 97 (2): 101–106. doi: 10.1136/archdischild-2011-300234Al Hosani H., Salah M., Osman H.M., Farag H.M., El Assiouty L., Saade D., Hertecant J. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. Eastern Mediterranean Health Journal, 2014; 20 (1): 17–23. doi: 10.26719/2014.20.1.17Al Hosani H., Salah M., Osman H.M., Farag H.M., El Assiouty L., Saade D., Hertecant J. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. Eastern Mediterranean Health Journal, 2014; 20 (1): 17–23. doi: 10.26719/2014.20.1.17Larrandaburu M., Matte U., Noble A., Olivera Z., Sanseverino M.T.V., Nacul L., Schuler-Faccini L. Ethics, genetics and public policies in Uruguay: newborn and infant screening as a paradigm. J. Commun. Genet., 2015; 6 (3): 241–249. doi: 10.1007/s12687-015-0236-2Larrandaburu M., Matte U., Noble A., Olivera Z., Sanseverino M.T.V., Nacul L., Schuler-Faccini L. Ethics, genetics and public policies in Uruguay: newborn and infant screening as a paradigm. J. Commun. Genet., 2015; 6 (3): 241–249. doi: 10.1007/s12687-015-0236-2Devi A.R.R., Naushad S.M. Newborn screening in India. Ind. J. Pediatr., 2004; 71 (2): 157–160. doi: 10.1007/bf02723099Devi A.R.R., Naushad S.M. Newborn screening in India. Ind. J. Pediatr., 2004; 71 (2): 157–160. doi: 10.1007/bf02723099Kaur G., Srivastav J., Jain S., Chawla D., Chavan B.S., Atwal R., Randhawa G., Kaur A., Prasad R. Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience. Ind. J. Pediatr., 2010; 77 (9): 969–973. doi: 10.1007/s12098-010-0150-xKaur G., Srivastav J., Jain S., Chawla D., Chavan B.S., Atwal R., Randhawa G., Kaur A., Prasad R. Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience. Ind. J. Pediatr., 2010; 77 (9): 969–973. doi: 10.1007/s12098-010-0150-xSteigert M., Schoenle E.J., Biason-Lauber A., Torresani T. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J. Clin. Endocrinol. Metab., 2002; 87 (9): 4106–4110. doi: 10.1210/jc.2002-012093Steigert M., Schoenle E.J., Biason-Lauber A., Torresani T. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J. Clin. Endocrinol. Metab., 2002; 87 (9): 4106–4110. doi: 10.1210/jc.2002-012093Larsson A., Thilén A., Hagenfeldt L., von Döbeln U., Guthenberg C. Screening of half a million Swedish newborn infants for congenital adrenal hyperplasia. Screening, 1992; 1 (3): 159–166. doi: 10.1016/09256164(92)90011-sLarsson A., Thilén A., Hagenfeldt L., von Döbeln U., Guthenberg C. Screening of half a million Swedish newborn infants for congenital adrenal hyperplasia. Screening, 1992; 1 (3): 159–166. doi: 10.1016/09256164(92)90011-sBalsamo A., Cacciari E., Piazzi S., Cassio A., Bozza D., Pirazzoli P., Zappulla F. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980–1995. Pediatrics, 1996; 98 (3 Pt 1): 362–367.Balsamo A., Cacciari E., Piazzi S., Cassio A., Bozza D., Pirazzoli P., Zappulla F. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980–1995. Pediatrics, 1996; 98 (3 Pt 1): 362–367.Cartigny-Maciejewski M., Guilley N., Vanderbecken S., Gondé S., Stuckens C., Ponté C., Weill J., Farriaux J.P. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980–1996. Archives de Pédiatrie, 1999; 6 (2): 151–158. doi: 10.1016/s0929-693x(99)80202-4Cartigny-Maciejewski M., Guilley N., Vanderbecken S., Gondé S., Stuckens C., Ponté C., Weill J., Farriaux J.P. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980–1996. Archives de Pédiatrie, 1999; 6 (2): 151–158. doi: 10.1016/s0929-693x(99)80202-4Lanting C.I., Verkerk P.H. Evaluatie van de screening op AGS/CHT/PKU bij kinderen geboren in 2002. Leiden: TNO Prevention and Health.Lanting C.I., Verkerk P.H. Evaluatie van de screening op AGS/CHT/PKU bij kinderen geboren in 2002. Leiden: TNO Prevention and Health.Stikkelbroeck M.M.L., van der Kamp H.J., Projectgroep AGS-screening. Neonatale screening op het adrenogenitaal syndroom (AGS), 1998–2001. RIVP rapport 199003063/2002. https://www.rivm.nl/publicaties/neonatale-screening-op-adrenogenitaal-syndroom-ags-1998-2001#abstract_enStikkelbroeck M.M.L., van der Kamp H.J., Projectgroep AGS-screening. Neonatale screening op het adrenogenitaal syndroom (AGS), 1998–2001. RIVP rapport 199003063/2002. https://www.rivm.nl/publicaties/neonatale-screening-op-adrenogenitaal-syndroom-ags-1998-2001#abstract_en
The authors declare that there are no conflicts of interest present.